Global Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Research Report 2024
Published on: 2024-01-04 | No of Pages : 400 | Industry : Medical
Publisher : MRA | Format : PDF
Global Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Research Report 2024
Polycystic ovarian syndrome (PCOS) is one of the most common endocrine disorders among women of reproductive age.
According to MRAResearch’s new survey, global Polycystic Ovarian Syndrome (PCOS) Therapeutics market is projected to reach US$ 4636.6 million in 2033, increasing from US$ 3740.4 million in 2022, with the CAGR of 3.1% during the period of 2023 to 2033. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Polycystic Ovarian Syndrome (PCOS) Therapeutics market research.
Key companies engaged in the Polycystic Ovarian Syndrome (PCOS) Therapeutics industry include Bristol Myers Squibb, Crinetics Pharmaceuticals, Inc., EffRx, Inc., Ferring Pharmaceuticals, Merck KGaA, Neurocrine Biosciences, Inc., Novartis Pharmaceuticals, Pfizer Inc. and Sanofi Aventis, etc. Among those companies, the top 3 players guaranteed % supply worldwide in 2022.
When refers to consumption region, % value of Polycystic Ovarian Syndrome (PCOS) Therapeutics were sold to North America, Europe and Asia Pacific in 2022. Moreover, China, plays a key role in the whole Polycystic Ovarian Syndrome (PCOS) Therapeutics market and estimated to attract more attentions from industry insiders and investors.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2033), aims to help readers to get a comprehensive understanding of global Polycystic Ovarian Syndrome (PCOS) Therapeutics market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Bristol Myers Squibb
Crinetics Pharmaceuticals, Inc.
EffRx, Inc.
Ferring Pharmaceuticals
Merck KGaA
Neurocrine Biosciences, Inc.
Novartis Pharmaceuticals
Pfizer Inc.
Sanofi Aventis
Teva Pharmaceutical Industries Limited
Segment by Type
Oral Contraceptive
Ovulation Inducing Agents
Facial Hair Growth Inhibitor
Insulin Sensitizing Agent
Hospitals
Clinic
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Polycystic Ovarian Syndrome (PCOS) Therapeutics report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Global market size, regional market size. Market Opportunities and Challenges
Chapter 3Companies’ Competition Patterns
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6 to 10Country Level Value Analysis
Chapter 11Companies' Outline
Chapter 12Market Conclusions
Chapter 13Research Methodology and Data Source
According to MRAResearch’s new survey, global Polycystic Ovarian Syndrome (PCOS) Therapeutics market is projected to reach US$ 4636.6 million in 2033, increasing from US$ 3740.4 million in 2022, with the CAGR of 3.1% during the period of 2023 to 2033. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Polycystic Ovarian Syndrome (PCOS) Therapeutics market research.
Key companies engaged in the Polycystic Ovarian Syndrome (PCOS) Therapeutics industry include Bristol Myers Squibb, Crinetics Pharmaceuticals, Inc., EffRx, Inc., Ferring Pharmaceuticals, Merck KGaA, Neurocrine Biosciences, Inc., Novartis Pharmaceuticals, Pfizer Inc. and Sanofi Aventis, etc. Among those companies, the top 3 players guaranteed % supply worldwide in 2022.
When refers to consumption region, % value of Polycystic Ovarian Syndrome (PCOS) Therapeutics were sold to North America, Europe and Asia Pacific in 2022. Moreover, China, plays a key role in the whole Polycystic Ovarian Syndrome (PCOS) Therapeutics market and estimated to attract more attentions from industry insiders and investors.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2033), aims to help readers to get a comprehensive understanding of global Polycystic Ovarian Syndrome (PCOS) Therapeutics market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Bristol Myers Squibb
Crinetics Pharmaceuticals, Inc.
EffRx, Inc.
Ferring Pharmaceuticals
Merck KGaA
Neurocrine Biosciences, Inc.
Novartis Pharmaceuticals
Pfizer Inc.
Sanofi Aventis
Teva Pharmaceutical Industries Limited
Segment by Type
Oral Contraceptive
Ovulation Inducing Agents
Facial Hair Growth Inhibitor
Insulin Sensitizing Agent
Segment by Application
Hospitals
Clinic
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Polycystic Ovarian Syndrome (PCOS) Therapeutics report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Global market size, regional market size. Market Opportunities and Challenges
Chapter 3Companies’ Competition Patterns
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6 to 10Country Level Value Analysis
Chapter 11Companies' Outline
Chapter 12Market Conclusions
Chapter 13Research Methodology and Data Source